Incidence, severity, and predictors of early postoperative dry eye disease following femtosecond laser-assisted in situ keratomileusis (FS-LASIK): a short-term, single-center retrospective analysis
International Ophthalmology · 2026
DOI: 10.1007/s10792-026-04222-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Ophthalmology, 2026. Verfasst von Lijuan Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, China. Hauptthemen laut MEDLINE: Keratomileusis, Laser In Situ, Dry Eye Syndromes, Postoperative Complications, Lasers, Excimer. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Dry eye disease (DED) is one of the most frequently reported complications following corneal refractive procedures, including femtosecond laser-assisted in situ keratomileusis (FS-LASIK). Despite the advanced precision of femtosecond technology, many patients experience postoperative ocular surface disturbances. OBJECTIVE: To assess the incidence, severity, and predictive factors of surgery-induced dry eye in patients undergoing femtosecond laser-assisted in situ keratomileusis, through a retrospective analysis. METHODS: This retrospective study included 3000 patients who underwent FS-LASIK between January 2020 to December 2024. Postoperative DED was defined by the Ocular Surface Disease Index (OSDI, score ≥ 13) at 1 week, 1 month, and 3 months; Schirmer's test was recorded preoperatively and for clinical interpretation only. Statistical analyses included chi-square tests and multivariable logistic regression to identify predictors of DED. RESULTS: Postoperative DED symptoms were reported in 25% of patients at 1 week, peaking at 38% at 1 month, and declining to 15% at 3 months. Most cases were mild to moderate. Female gender (OR: 2.51, p = 0.003) and preoperative DED (OR: 4.79, p < 0.001) were significant independent predictors of postoperative symptoms. Age did not show a significant association. By three months, the symptoms had significantly improved; however, further monitoring is necessary to assess full recovery and long-term results. CONCLUSION: DED is a common but typically transient outcome following FS-LASIK, particularly in female patients and those with preoperative symptoms. Structured preoperative screening, patient counselling, and individualised postoperative care are essential to improving outcomes and minimising patient discomfort. Because follow-up was limited to three months, these findings characterise early postoperative dry eye and do not address long-term persistence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, China.
- Department of Ophthalmology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, Fujian, China. cuirl8803@163.com.
Zitieren
APA
Wu, L., Xie, X., Lai, M., Fan, X., & Lin, C. (2026). Incidence, severity, and predictors of early postoperative dry eye disease following femtosecond laser-assisted in situ keratomileusis (FS-LASIK): a short-term, single-center retrospective analysis. International Ophthalmology. https://doi.org/10.1007/s10792-026-04222-4
Vancouver
Wu L, Xie X, Lai M, Fan X, Lin C. Incidence, severity, and predictors of early postoperative dry eye disease following femtosecond laser-assisted in situ keratomileusis (FS-LASIK): a short-term, single-center retrospective analysis. International Ophthalmology. 2026. doi:10.1007/s10792-026-04222-4
BibTeX
@article{Wu2026,
author = {Wu, Lijuan and Xie, Xiaolan and Lai, Meihua and Fan, Xiaolin and Lin, Cuirong},
title = {Incidence, severity, and predictors of early postoperative dry eye disease following femtosecond laser-assisted in situ keratomileusis (FS-LASIK): a short-term, single-center retrospective analysis},
journal = {International Ophthalmology},
year = {2026},
doi = {10.1007/s10792-026-04222-4}
}
EUVIMED